These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 6846326)

  • 41. Fibrin moderates the catalytic action of heparin but not that of dermatan sulfate on thrombin inhibition in human plasma.
    Okwusidi JI; Anvari N; Kulczycky M; Blajchman MA; Buchanan MR; Ofosu FA
    J Lab Clin Med; 1991 May; 117(5):359-64. PubMed ID: 2019790
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Complex formation with protamine prolongs the thrombin-inhibiting effect of DNA aptamer in vivo.
    Spiridonova VA; Novikova TM; Nikulina DM; Shishkina TA; Golubkina EV; Dyukareva OS; Trizno NN
    Biochimie; 2018 Feb; 145():158-162. PubMed ID: 28935443
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro and in vivo characterization of a reversible synthetic heparin analog.
    Whelihan MF; Cooley B; Xu Y; Pawlinski R; Liu J; Key NS
    Thromb Res; 2016 Feb; 138():121-129. PubMed ID: 26709038
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inhibition of heparin activity in plasma by soluble fibrin: evidence for ternary thrombin-fibrin-heparin complex formation.
    Hotchkiss KA; Chesterman CN; Hogg PJ
    Blood; 1994 Jul; 84(2):498-503. PubMed ID: 8025278
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A comparison of the quantitative action of protamine and heparin on blood coagulation. Significance in clinical and laboratory usage.
    Perkash A
    Am J Clin Pathol; 1980 May; 73(5):676-81. PubMed ID: 7377134
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The additive effect of low molecular weight heparins on thrombin inhibition by dermatan sulfate.
    Cosmi B; Agnelli G; Young E; Hirsh J; Weitz J
    Thromb Haemost; 1993 Sep; 70(3):443-7. PubMed ID: 8259546
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Neutralization of low molecular weight heparin Kabi 2165 by protamine chloride].
    Harenberg J; Giese C; Knödler A; Zimmermann R; Schettler G
    Klin Wochenschr; 1986 Nov; 64(22):1171-5. PubMed ID: 3807263
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anticoagulant and antiheparin activities of a pentosan polysulphate.
    Scully MF; Weerasinghe KM; Ellis V; Djazaeri B; Kakkar VV
    Thromb Res; 1983 Jul; 31(1):87-97. PubMed ID: 6193602
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The pharmacological profile of the low molecular weight heparin 21-23 in man: anticoagulant, lipolytic and protamine reversible effects.
    Harenberg J; Stehle G; Dempfle CE; von Hodenberg E; Heene DL
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(6):967-80. PubMed ID: 2483715
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anticoagulant and antiprotease profiles of a novel natural heparinomimetic mannopentaose phosphate sulfate (PI-88).
    Demir M; Iqbal O; Hoppensteadt DA; Piccolo P; Ahmad S; Schultz CL; Linhardt RJ; Fareed J
    Clin Appl Thromb Hemost; 2001 Apr; 7(2):131-40. PubMed ID: 11292191
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of glycosaminoglycans and antithrombin III on uptake and inhibition of thrombin by the vascular wall.
    Dryjski M; Larsson R; Olsson P; Swedenborg J
    Thromb Res; 1983 Nov; 32(4):355-63. PubMed ID: 6658719
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery.
    Nimjee SM; Keys JR; Pitoc GA; Quick G; Rusconi CP; Sullenger BA
    Mol Ther; 2006 Sep; 14(3):408-15. PubMed ID: 16765093
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ability of high-affinity heparin fractions with decreasing affinity for antithrombin III to activate ATIII isoforms.
    Carlson TH; Kolman MR; Frees A; Babcock T
    Thromb Res; 1990 Aug; 59(3):521-30. PubMed ID: 2237824
    [TBL] [Abstract][Full Text] [Related]  

  • 54. alpha-Thrombin within fibrin clots: inactivation of thrombin by antithrombin-III.
    Naski MC; Shafer JA
    Thromb Res; 1993 Mar; 69(5):453-65. PubMed ID: 8497860
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Protamine sulfate neutralization of the anticoagulant activity of Aprosulate, a synthetic sulfated lactobionic acid amide.
    Kijowski R; Hoppensteadt D; Jeske W; Fareed J
    Thromb Res; 1994 Mar; 73(5):349-59. PubMed ID: 8016819
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The mechanism of anticoagulant activity of a novel heparinoid sulfated glucoside-bearing polymer.
    Sakamoto N; Kishida A; Maruyama I; Akashi M
    J Biomater Sci Polym Ed; 1997; 8(7):545-53. PubMed ID: 9195333
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Thrombin generation during cardiac surgery: is heparin the ideal anticoagulant?
    Brister SJ; Ofosu FA; Buchanan MR
    Thromb Haemost; 1993 Aug; 70(2):259-62. PubMed ID: 8236131
    [TBL] [Abstract][Full Text] [Related]  

  • 58. On the mechanism of coagulation inhibition on surfaces with end point immobilized heparin.
    Elgue G; Blombäck M; Olsson P; Riesenfeld J
    Thromb Haemost; 1993 Aug; 70(2):289-93. PubMed ID: 8236137
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Binding of antithrombin III and thrombin to immobilized heparin under flow conditions.
    Byun Y; Jacobs HA; Kim SW
    Biotechnol Prog; 1996; 12(2):217-25. PubMed ID: 8857192
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The hyperglycemic byproduct methylglyoxal impairs anticoagulant activity through covalent adduction of antithrombin III.
    Jacobson R; Mignemi N; Rose K; O'Rear L; Sarilla S; Hamm HE; Barnett JV; Verhamme IM; Schoenecker J
    Thromb Res; 2014 Dec; 134(6):1350-7. PubMed ID: 25307422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.